ANAreesha Nawaz

Areesha Nawaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Areesha Nawaz has a total of 31 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Two decades of pulmonary vascular disease and ischemic heart disease mortality in the united states: A longitudinal analysis using CDC WONDER (1999–2020)

    by Areesha Nawaz, Fnu Hafeezullah, Zainab Ali Siddiqui, Muhammad Shaheer Bin Faheem, Nazeer Ahmed, Razeena Zahid, Ali Zubair, Bushra Ghullam Muhammad, Jawad Ibrahim, Muhammad Raafay Jamil, et al.

    Pulmonary vascular disease (PVD) and ischemic heart disease (IHD) are major contributors to cardiovascular mortality in U.S. adults. This retrospective study aims to examine mortality trends and demographic disparities between 1999 and 2020. However, both diseases have been studied individually, but their combined temporal trends remain unexplored. The CDC WONDER database was used to obtain data for adults aged ≥ 45 years. AAMRs per 100,000 population and APC were calculated using Joinpoint regression, stratified by demographic, geographic, and urbanization categories. PVD and IHD together reported a total of 184,780 deaths. The overall AAMR increased from 6.9 to 8.9 per 100,000 between 1999 and 2020. Mortality rates were higher in men (8.8) compared to females (6.0) throughout the study period. Black or African American individuals had the highest AAMR (8.9), demonstrating a current surge in 2018. Similarly, non-metropolitan areas consistently experienced greater AAMR (8.5) than metropolitan areas (6.9), with a steep rise after 2018 (APC = 14.72%). Furthermore, mortality was greatest in the South; however, the Midwest region reported the highest AAMRs (8). Additionally, individuals aged 85 + had the highest CMR (44.6). Lastly, Vermont had the highest AMMRs (13.6) among other states. PVD- and IHD-related mortality depicted a recent steep increase despite an initial decline, with considerable differences across demographic and regional groups. This highlights the importance of a direct call to action by expanding preventive care, spreading awareness, and early diagnosis with management to address these inequities and decrease the growing burden.

  • Trends in Alzheimer's disease mortality with metabolic syndrome–related conditions among older adults in the United States, 1999–2020

    by Taha Alam, Dhvanit Rajdeep, Sohaima Kamal, Iman Osman Abufatima, Mominah Majid, Sadaf Siddiqui, Syed Ali Waheed, Areesha Nawaz, Muhammad Shaheer Bin Faheem, Waqas Burney, et al.

    Background: Alzheimer's disease (AD) among patients with metabolic syndrome-related conditions is a global threat, contributing significantly to escalating mortality and economic burden. They demonstrate analogous pathophysiologies and risk determinants, highlighting the necessity for addressing this critical issue. Objective: This study analyzed demographic trends and disparities of AD with metabolic syndrome-related conditions among patients aged 75 and above from 1999 to 2020. Methods: This study examined the death certificates sourced from the CDC-WONDER database from 1999 to 2020, to analyze age-adjusted mortality rates (AAMRs) per 100,000 population. The Joinpoint regression model was used to assess trends in overall demographics, geographic, and place-of-death variables. Results: There were 2,355,233 deaths documented with AD listed as the underlying cause of death among older adults (aged ≥75), out of which 444,488 deaths were related to metabolic syndrome-related conditions from 1999 to 2020. The AAMR rose substantially from 36.48 in 1999 to 157.93 in 2020. Women consistently had higher AAMRs than males (females: 107.79, males: 79.02). Non-Hispanic African Americans (121.65) showed the highest mortality rates among all racial groups. However, from 1999 to the early to mid-2000s, all races highlighted a sharp peak in mortality rates. Striking geographical disparities were noted, with Mississippi in the top 90 th percentile and Massachusetts in the lower 10 th percentile. Conclusions: This study reveals the demographic and geographic variations in mortality rates, highlighting the modalities of interventions and the need for equitable healthcare access.

  • Open Access

    Immunophenotypes and prognosis in autoimmune cardiovascular disease: a narrative review from clonal hematopoiesis to myocarditis, microvascular angina, and HFpEF

    by Suleman Khan, Fakhar e Mahin, Ibad Ur Rahman, Asifa Manzoor Ahmad, Areesha Nawaz, Zainab Ali Siddiqui, Aizaz Anwar Khalid, Hammad Iftikhar, Nawras Fashafsheh

    Autoimmune cardiovascular disease (CVD) includes myocarditis, coronary microvascular dysfunction (CMD), and heart failure with preserved ejection fraction (HFpEF). Traditional risk scores often overlook these conditions despite their links to high morbidity. Recent research highlights the significance of immunophenotyping, such as clonal hematopoiesis of indeterminate potential (CHIP), type I interferon activity, Th17/Treg imbalance, and cardiac autoantibodies, to improve risk assessment and guide treatment. This review combines mechanistic and clinical data connecting these immune signatures to endothelial dysfunction, arrhythmias, and fibrotic remodeling. It underscores the atherogenic role of CHIP and its influence on HFpEF prognosis, the vasculopathy driven by type I interferon signaling in CMD, and autoimmunity in myocarditis mediated by Th17 dominance. Cardiac-specific autoantibodies, like anti-heart and v1-adrenergic receptor antibodies, serve as early prognostic markers. Moreover, integrating immune biomarkers with advanced imaging techniques, such as cardiac magnetic resonance and positron emission tomography, could enhance risk stratification and therapy monitoring. Current immunomodulating treatments, including TNF and IL-6 inhibitors, provide cardiovascular benefits, while glucocorticoids and JAK inhibitors carry dose-related risks. In the future, personalized algorithms that incorporate CHIP genotyping, interferon scoring, and continuous biomarker and imaging assessments may transform autoimmune CVD management. This review highlights these translational insights and research priorities to bridge the gap between immune dysregulation and cardiovascular outcomes.


  • Trends in pulmonary embolism mortality among older adults with lung cancer in the united States, 1999–2020

    by Fnu Hafeezullah, Areesha Nawaz, Fnu Areesha, Muhammad Wassam, Muhammad Shaheer Bin Faheem, Razeena Zahid, Summaiya Salman, Muhammad Raafay Jamil

    Highlights This nationwide study analyzed mortality trends in U.S. adults aged 65 years and above, pulmonary embolism mortality among older adults with lung cancer in the United States, 1999–2020. Age-adjusted mortality rates (AAMRs) escalated substantially during the study period, with consistently higher rates observed in men and older age groups. The racial groups showed that the highest AAMRs were exhibited by the Non-Hispanic Blacks, followed by the Non-Hispanic Whites and other races. Non-metropolitan populations and residents of the Midwest and Northeast census regions endured heightened mortality rates, emphasizing the necessity for intervention modalities in the underserved communities.